Send this to a friend

Bristol Myers-Squibb to acquire Celgene for $74B

Bristol-Myers Squibb, with a biologics development facility in Devens, is purchasing New Jersey-based Celgene Corp. for $74 billion.
The New York City-based pharmaceutical company announced the cash and stock agreement Tuesday. Per the the deal, Celgene shareholders will get one Bristol-Myers Squibb share and $50 in cash for each share of Celgene. 
Celgene shareholders will also get one tradeable contingent ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media